Moreover, 2FF treatment at two different doses in a prophylactic anti-tumor experimental setting delayed tumor formation, prevented cancer development in 33% of TgMMTV-neu and 26% of C3(1)-Tag models, and enhanced splenocyte reactogenicity upon exposure to tumor-lysate. The gene discussed is ERBB2; the disease is neoplasm.